Who We Are
Gyder Surgical is an Australian MedTech company specializing in intuitive, non-invasive orthopaedic navigation products.
We believe that every patient should have access to accurate and precise surgery, no matter where they are. We are building products that work in a wide variety of care settings – Ambulatory / Outpatient Surgery Centers or large ORs in hospitals.
We believe that the best solutions minimize complexity and do not require surgeons to significantly change their practice. The GYDER™ Hip Navigation System, our first product, is designed to assist surgeons accurately place the acetabular cup during hip surgery.
The Origin of Gyder Surgical
Gyder Surgical was formed by Bob Lye to develop and commercialise the GYDER™ System.
Bob started his career with QANTAS where he trained in aircraft instrument systems. In the 1990s Bob left QANTAS and acquired MAC Surgical, a company specialising in the orthopaedic instruments for leading manufacturers. As Bob began to work closely with surgeons he became aware of their challenge when positioning the acetabular cup in the pelvis during hip replacement procedures. Bob’s background gave him a unique perspective on this problem and he applied modern aeronautical navigation techniques to the acetabular cup challenge. This led to invention of the GYDER™ System.
Sujit serves as the CEO and is a member of the Board of Directors at Gyder Surgical. He has extensive healthcare industry experience in Orthopedics, General Surgery, Imaging, Navigation and Genomics.
Prior to joining Gyder, Sujit worked at global healthcare organizations (Johnson & Johnson, Synthes), a pioneer in gene sequencing technology (Affymetrix) and a startup developing breakthrough exoskeleton technology. His experience spans Account Management, Sales, Marketing, Strategic, and Research & Development roles. At Johnson & Johnson, he was Vice President of the MedTech Surgery Centers group, where he led teams to accelerate growth in this emerging channel.
Sujit has an MBA from the Wharton School, a Masters in Biochemistry and Molecular Biology from SUNY Stony Brook and undergraduate degree in Biotechnology & Biochemical Engineering from the Indian Institute of Technology, Delhi. He is the lead and co-author of 9+ peer-reviewed publications in leading scientific journals including Nature Genetics, Genome Research and Science. And is a recipient of the US Dept of Agriculture award for significant contributions to the global rice genome sequencing initiative.
Bill Hill is a seasoned senior executive and has over 25 years of experience leading high-technology companies.
Prior to Gyder Surgical, Bill held senior positions at two of Australia’s leading development companies as General Manager of Strategic Business Development at Hydrix and Business Unit Director at Invetech.
Bill was a member of the National Executive of the Australian Industry Research Group (AIRG) from June 2015 until June 2017 and was a Commercialisation Expert Peer Reviewer for National Health and Medical Research Council (NHMRC) Development Grants in 2016 and 2017.
He holds a Bachelor of Science in Applied Physics with Honours from Strathclyde University and an MBA from RMIT University.
BOARD OF DIRECTORS
Lawrence Gozlan is a leading biotechnology investor and advisor, the Life Sciences Investment Manager at Jagen Pty Ltd an international private investment organisation. Lawrence is also the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences.
Lawrence has 20 years of experience in investing and banking, with expertise in all areas of investment management and deep roots in the scientific and biotech communities.
Prior to Scientia, Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over $60 billion under management.
Lawrence currently serves as a Director on the Board of Alterity Therapeutics (NASDAQ: ATHE), Opthea (ASX:OPT), and Faraday Pharmaceuticals. He holds a Bachelor of Science with Honours in Immunology from the University of Melbourne.
Dr. Nicholas Pachuda
Dr. Nicholas Pachuda serves as the SVP of Portfolio & Development at Peptilogics and has approximately 28 years of clinical and industry experience in life sciences including orthopedics/medtech and biotech.
These included senior R&D, Clinical, Innovation, BD and Commercial P&L leadership roles. He was involved with several successful startups, midcaps and multinationals, including 10 years at Johnson & Johnson. He has led multiple global organic and inorganic development programs with diverse technologies and teams. Dr. Pachuda was trained as a foot and ankle surgeon and completed an international orthopedic trauma fellowship.
Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. Sonic healthcare has a market capitalisation of over $20 Billion and is one of the largest medical diagnostic companies in the world.
He has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a Non-Executive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996. Chris holds a Bachelor of Commerce from Melbourne University.
Mark Brydon sold Hydrix, a company he built into one of Australia’s largest independent MedTech product development companies, in the latter half of 2017.
Under Mark’s leadership, Hydrix grew to a team of 60+ top-flight engineers and designers successfully winning advanced medical R&D projects from around the world.
Prior to Hydrix, Mark was a senior project manager with Robert Bosch where he led teams of engineers in the development of cutting-edge automotive systems, and before that with Hewlett Packard (HP) overseeing the developing of advanced calculators and digital devices.
Mark now holds a number of directorships and provides independent advisory services.
Mark has an Engineering Degree from RMIT University and has undertaken post-graduate Project Management qualifications.
Our technology development partner
Hydrix is a specialist product development and engineering company with a focus in medtech. Hydrix’s engineering capability coupled with in-house regulatory consulting made them a natural partner to develop the GYDER™ System.
Gyder Surgical has worked with Hydrix since 2018 to develop the GYDER™ System and transfer the design to our manufacturing partners.
In addition to being our development partner, we are pleased that Hydrix is also an investor in Gyder Surgical.
Our global manufacturing partner
SRX Global is a leading provider of superior quality electronic manufacturing for high-technology customers through all phases of the product’s life cycle. SRX provide a wide range of Electronic Manufacturing Services (EMS) across MedTech, industrial, defence, communications and automotive
SRX has supported Gyder Surgical’s electronic manufacturing needs from prototype development through to establishing production. The company’s highly skilled electronic engineers ensure that the high levels of quality necessary for medical devices are achieved on finished products.
Our packaging partner
Sabre Medical is a leading developer of packaging solutions and provider of cleaning, assembly, packaging, and sterilisation services to medical device companies.
Our innovation consultants partner
Vestech is a highly experienced team of medical device innovation consultants with deep domain knowledge in orthopaedic products. Dr Greg Roger, Vestech founder and surgeon plus his team have been working with Gyder Surgical providing specialist clinical and regulatory advice to ensure the GYDER™ System meets the rigorous regulatory requirements for medical devices.
GET IN TOUCH
Want to know more us? Get in touch today, we'd love to hear from you.